Proteolytic instability has long hindered the clinical development of therapeutic peptides. However, researchers have recently developed stable oncolytic peptides using a novel MeLysine-stapling strategy. Specifically, by cross-linking alpha-methyl-substituted lysine residues, scientists engineered a series of stabilized analogues, including the lead candidate MeLS-5. This modification significantly enhances the peptide's resistance to enzymatic degradation.

Mechanism and Efficacy of Stable Oncolytic Peptides

MeLS-5 demonstrates an exceptional serum half-life exceeding 48 hours. This represents a 32-fold increase compared to the unmodified parent peptide. Consequently, the peptide remains active in the systemic circulation for a much longer duration. Mechanistically, MeLS-5 targets cancer cells by rapidly and irreversibly disrupting their membranes. Because this physical disruption occurs regardless of metabolic pathways, cancer cells struggle to develop resistance. Furthermore, the peptide exhibits potent broad-spectrum cytotoxicity across various cancer cell lines with an average IC50 of 3.9 μM.

In preclinical studies, MeLS-5 showed impressive results using a syngeneic 4T1 xenograft model. Specifically, intravenous administration of 5 mg/kg every other day inhibited tumor growth by 63%. Moreover, the researchers observed no systemic toxicity or exacerbated pathologies during the treatment. Therefore, this dual-modification strategy—combining MeLysine-stapling and N-terminal acetylation—offers a robust pathway for engineering future peptide therapeutics. Ultimately, MeLS-5 stands out as a promising preclinical candidate for advanced oncological treatments.

Frequently Asked Questions

What is MeLysine-stapling in the context of stable oncolytic peptides?

MeLysine-stapling is a chemical engineering strategy involving the intramolecular cross-linking of alpha-methyl-substituted lysine residues. This process stabilizes the peptide structure, making it highly resistant to proteolytic enzymes that usually break down peptides in the blood.

How does N-terminal acetylation contribute to peptide stability?

N-terminal acetylation protects the end of the peptide chain from aminopeptidases. When combined with MeLysine-stapling, it provides a dual layer of protection that dramatically extends the therapeutic window and half-life of the peptide.

Are stable oncolytic peptides like MeLS-5 safe for normal cells?

Preclinical data indicates that MeLS-5 possesses low toxicity toward human erythrocytes and normal mammalian cells. It specifically targets the distinctive biophysical properties of cancer cell membranes, which minimizes the risk of off-target systemic effects.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

1. Xu L et al. MeLysine-Stapling Combined with N-Terminal Acetylation Yields Stable Oncolytic Peptides with Enhanced Antitumor Efficacy. J Med Chem. 2026 May 19. doi: 10.1021/acs.jmedchem.6c00009. PMID: 42153364.

2. Li et al. Stapled wasp venom-derived oncolytic peptides with side chains induce rapid membrane lysis and prolonged immune responses in melanoma. J Med Chem. 2021;64(9):5802-5815. doi: 10.1021/acs.jmedchem.0c02237.

3. Vernen F et al. Characterization of tachyplesin peptides and their cyclized analogues to improve antimicrobial and anticancer properties. Int J Mol Sci. 2019;20(17):4184. doi: 10.3390/ijms20174184.